Breaking News, Collaborations & Alliances

Vanda Pharmaceuticals, OliPass Enter ASO R&D Alliance

Aims to jointly develop a set of antisense oligonucleotide (ASO) molecules based on OliPass' modified peptide nucleic acids.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Vanda Pharmaceuticals Inc. and OliPass Corp. have entered into a research and development collaboration to jointly develop a set of antisense oligonucleotide (ASO) molecules based on OliPass’ modified peptide nucleic acids. The partnership leverages the respective strengths of Vanda and OliPass to support the development of ASO-based precision medicine therapeutics and potentially create compelling value opportunities for both companies.   The collaboration will focus on editing and modi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters